MapLight Therapeutics/$MPLT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MapLight Therapeutics
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders. Founded in 2019 by experts in psychiatry and neuroscience, the company employs proprietary technologies such as optogenetics, STARmap, and transcriptomics to identify and target neural circuits linked to various CNS conditions. Its lead product candidate, ML-007C-MA, is an oral, extended-release, fixed-dose combination of an investigational M₁/M₄ muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic, currently in Phase 2 clinical trials for schizophrenia and Alzheimer's disease psychosis. Other pipeline programs include ML-004, a 5-HT₁B agonist in Phase 2 targeting social communication deficits in autism spectrum disorder, and preclinical compounds ML-016 and ML-009 for Parkinson’s disease and hyperactivity/impulsivity, respectively. Headquartered in Redwood City, California, MapLight has secured significant funding, including a $372.5 million Series D financing in July 2025, and announced its initial public offering on October 6, 2025, with shares expected to begin trading on the Nasdaq Global Market under the symbol "MPLT" on October 27, 2025.
Ticker
$MPLT
Sector
Primary listing
Employees
109
Headquarters
Website
MPLT Metrics
BasicAdvanced
$694M
-
-$121.50
-
-
Price and volume
Market cap
$694M
52-week high
$20.86
52-week low
$16.75
Financial strength
Current ratio
4.885
Quick ratio
4.036
Long term debt to equity
8.425
Total debt to equity
9.732
Profitability
EBITDA (TTM)
-97.193
Management effectiveness
Valuation
Price to book
-0.05
Price to tangible book (TTM)
-0.05
Price to free cash flow (TTM)
-0.126
Free cash flow yield (TTM)
-795.80%
Free cash flow per share (TTM)
-133.295
Growth
Bulls say / Bears say
MapLight closed an oversubscribed $372.5 million Series D in July 2025, with Forbion and Goldman Sachs Alternatives as lead investors. This gives the company plenty of capital to advance both clinical and preclinical projects. (Reuters)
During its IPO in October 2025, MapLight raised $250.8 million at $17 a share, reaching a valuation up to $704.3 million. The offering came as biotech IPO activity rebounded, reflecting investor enthusiasm for its central nervous system platform. (Reuters)
MapLight’s pipeline is diversified, with ML-007C-MA and ML-004 in Phase 2 for schizophrenia, Alzheimer’s-related psychosis, and autism spectrum disorder, as well as preclinical programs for Parkinson’s and hyperactivity. This breadth provides multiple near-term clinical catalysts. (Reuters)
MapLight reported a net loss of $52.2 million for the first half of 2025, up from $37.3 million a year earlier, highlighting continued high R&D expenses without any commercial revenue to offset costs. (Reuters)
The company’s SEC filings show its IND application for ML-007C-MA was placed on clinical hold by the FDA in May 2024 due to nonclinical findings, pointing to potential regulatory hurdles that could delay key Phase 2 studies. (StreetInsider)
With no approved products and a post-IPO valuation near $704.3 million, MapLight is highly exposed to the binary risk of mid-stage clinical trials and uncertain regulatory approvals, which could significantly increase share volatility. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2025.
MPLT Financial Performance
Revenues and expenses
MPLT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MapLight Therapeutics stock?
MapLight Therapeutics (MPLT) has a market cap of $694M as of October 29, 2025.
What is the P/E ratio for MapLight Therapeutics stock?
The price to earnings (P/E) ratio for MapLight Therapeutics (MPLT) stock is 0 as of October 29, 2025.
Does MapLight Therapeutics stock pay dividends?
No, MapLight Therapeutics (MPLT) stock does not pay dividends to its shareholders as of October 29, 2025.
When is the next MapLight Therapeutics dividend payment date?
MapLight Therapeutics (MPLT) stock does not pay dividends to its shareholders.
What is the beta indicator for MapLight Therapeutics?
MapLight Therapeutics (MPLT) does not currently have a Beta indicator.